Last reviewed · How we verify
aspirin and meloxicam
At a glance
| Generic name | aspirin and meloxicam |
|---|---|
| Also known as | generic, not applicable |
| Sponsor | Vanderbilt University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PROUD Study - Preventing Opioid Use Disorders (PHASE4)
- Aspirin Resistance in Systemic Lupus Erythematosus (SLE) (PHASE1)
- The Effect on Knee Joint Loads of Analgesic Use Compared With Exercise in Patients With Knee Osteoarthritis - An RCT (NA)
- Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin and meloxicam CI brief — competitive landscape report
- aspirin and meloxicam updates RSS · CI watch RSS
- Vanderbilt University portfolio CI